170 related articles for article (PubMed ID: 20735874)
21. Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis.
Rugo HS; Melin SA; Voigt J
Breast Cancer Res Treat; 2017 Jun; 163(2):199-205. PubMed ID: 28275922
[TBL] [Abstract][Full Text] [Related]
22. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
[TBL] [Abstract][Full Text] [Related]
23. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
[TBL] [Abstract][Full Text] [Related]
25. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
Diel IJ; Solomayer EF; Costa SD; Gollan C; Goerner R; Wallwiener D; Kaufmann M; Bastert G
N Engl J Med; 1998 Aug; 339(6):357-63. PubMed ID: 9691101
[TBL] [Abstract][Full Text] [Related]
26. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer.
Recht A; Come SE; Henderson IC; Gelman RS; Silver B; Hayes DF; Shulman LN; Harris JR
N Engl J Med; 1996 May; 334(21):1356-61. PubMed ID: 8614420
[TBL] [Abstract][Full Text] [Related]
27. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment.
Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G
Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359
[TBL] [Abstract][Full Text] [Related]
28. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.
Stemmer SM; Pfeffer MR; Rizel S; Hardan I; Goffman J; Gezin A; Neumann A; Kitsios P; Alezra D; Brenner HJ
Cancer; 2001 Jun; 91(11):1983-91. PubMed ID: 11391576
[TBL] [Abstract][Full Text] [Related]
29. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
Stadtmauer EA; O'Neill A; Goldstein LJ; Crilley PA; Mangan KF; Ingle JN; Brodsky I; Martino S; Lazarus HM; Erban JK; Sickles C; Glick JH
N Engl J Med; 2000 Apr; 342(15):1069-76. PubMed ID: 10760307
[TBL] [Abstract][Full Text] [Related]
30. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
Moebus V; Jackisch C; Lueck HJ; du Bois A; Thomssen C; Kurbacher C; Kuhn W; Nitz U; Schneeweiss A; Huober J; Harbeck N; von Minckwitz G; Runnebaum IB; Hinke A; Kreienberg R; Konecny GE; Untch M
J Clin Oncol; 2010 Jun; 28(17):2874-80. PubMed ID: 20458045
[TBL] [Abstract][Full Text] [Related]
31. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
Zander AR; Kröger N; Schmoor C; Krüger W; Möbus V; Frickhofen N; Metzner B; Schultze W; Berdel WE; Koenigsmann M; Thiel E; Wandt H; Possinger K; Trümper L; Kreienberg R; Carstensen M; Schmidt EH; Jänicke F; Schumacher M; Jonat W
J Clin Oncol; 2004 Jun; 22(12):2273-83. PubMed ID: 15111618
[TBL] [Abstract][Full Text] [Related]
32. TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer.
Razis ED; Samonis G; Cook P; Beer M; Mittelman A; Lake DE; Feldman EJ; Puccio C; Ahmed T
J Med; 1994; 25(3-4):241-50. PubMed ID: 7996067
[TBL] [Abstract][Full Text] [Related]
33. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
34. [High dose chemotherapy in treatment of breast carcinoma: current status and limits of this method of therapy].
Derigs HG; Huber C; Mahlke M; Kolbe K
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):190-7. PubMed ID: 8682284
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
36. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of high-dose chemotherapy and autologous stem cell transplant in isolated locally recurrent breast cancer: a multicenter evaluation.
Vij R; DiPersio J; Brown R; Trinkaus K; Abboud C; Meehan KR; Frenette G; Freytes C; Goodnough LT; Khoury H; Ponnuri J; Adkins D
Bone Marrow Transplant; 2000 Nov; 26(9):947-53. PubMed ID: 11100273
[TBL] [Abstract][Full Text] [Related]
38. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
Rugo HS; Klein P; Melin SA; Hurvitz SA; Melisko ME; Moore A; Park G; Mitchel J; Bågeman E; D'Agostino RB; Ver Hoeve ES; Esserman L; Cigler T
JAMA; 2017 Feb; 317(6):606-614. PubMed ID: 28196257
[TBL] [Abstract][Full Text] [Related]
39. Impact of alopecia and scalp cooling on the well-being of breast cancer patients.
van den Hurk CJ; Mols F; Vingerhoets AJ; Breed WP
Psychooncology; 2010 Jul; 19(7):701-9. PubMed ID: 19637250
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy.
Cigler T; Isseroff D; Fiederlein B; Schneider S; Chuang E; Vahdat L; Moore A
Clin Breast Cancer; 2015 Oct; 15(5):332-4. PubMed ID: 25749072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
